CN101716167A - 一类饱和胺类化合物在制备外周血造血干细胞动员药物中的应用 - Google Patents
一类饱和胺类化合物在制备外周血造血干细胞动员药物中的应用 Download PDFInfo
- Publication number
- CN101716167A CN101716167A CN200910241726A CN200910241726A CN101716167A CN 101716167 A CN101716167 A CN 101716167A CN 200910241726 A CN200910241726 A CN 200910241726A CN 200910241726 A CN200910241726 A CN 200910241726A CN 101716167 A CN101716167 A CN 101716167A
- Authority
- CN
- China
- Prior art keywords
- hematopoietic stem
- peripheral blood
- stem cells
- amine compound
- medicaments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000005259 peripheral blood Anatomy 0.000 title claims abstract description 30
- 239000011886 peripheral blood Substances 0.000 title claims abstract description 30
- 210000003958 hematopoietic stem cell Anatomy 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 title claims abstract description 18
- -1 amine compound Chemical class 0.000 title claims abstract description 16
- 229920006395 saturated elastomer Polymers 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 230000001483 mobilizing effect Effects 0.000 title abstract 5
- 238000002347 injection Methods 0.000 claims description 19
- 239000007924 injection Substances 0.000 claims description 19
- 150000001412 amines Chemical class 0.000 claims description 8
- 239000007984 Tris EDTA buffer Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 14
- 238000002474 experimental method Methods 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 27
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 19
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 19
- 238000002156 mixing Methods 0.000 description 19
- 210000000130 stem cell Anatomy 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 210000001185 bone marrow Anatomy 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 7
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- 229960004756 ethanol Drugs 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000011476 stem cell transplantation Methods 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 3
- 230000002607 hemopoietic effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- CHZXTOCAICMPQR-UHFFFAOYSA-N 2-(2-bromoethyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCBr)C(=O)C2=C1 CHZXTOCAICMPQR-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000009395 genetic defect Effects 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 210000001357 hemopoietic progenitor cell Anatomy 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- CYMRPDYINXWJFU-UHFFFAOYSA-N 2-carbamoylbenzoic acid Chemical compound NC(=O)C1=CC=CC=C1C(O)=O CYMRPDYINXWJFU-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
- 244000050510 Cunninghamia lanceolata Species 0.000 description 1
- 201000004939 Fanconi anemia Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 235000011158 Prunus mume Nutrition 0.000 description 1
- 244000018795 Prunus mume Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 208000002152 Splenic rupture Diseases 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000024340 acute graft versus host disease Diseases 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- VFBJEDFCUUCMBQ-UHFFFAOYSA-O azanium;sodium;antimony(3+);oxygen(2-);tungsten Chemical compound [NH4+].[O-2].[Na+].[Sb+3].[W] VFBJEDFCUUCMBQ-UHFFFAOYSA-O 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 208000017760 chronic graft versus host disease Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- JAWGVVJVYSANRY-UHFFFAOYSA-N cobalt(3+) Chemical compound [Co+3] JAWGVVJVYSANRY-UHFFFAOYSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (5)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009102417263A CN101716167B (zh) | 2009-12-08 | 2009-12-08 | 一类饱和胺类化合物在制备外周血造血干细胞动员药物中的应用 |
US13/514,873 US20120322886A1 (en) | 2009-12-08 | 2010-12-08 | Use of a saturated amines compound in manufacture of medicaments for mobilizing peripheral blood hematopoietic stem cell |
PCT/CN2010/001986 WO2011069336A1 (zh) | 2009-12-08 | 2010-12-08 | 一类饱和胺类化合物在制备外周血造血干细胞动员剂中的应用 |
JP2012542340A JP5667640B2 (ja) | 2009-12-08 | 2010-12-08 | 末梢血造血幹細胞動員剤の生産における飽和アミン化合物の使用 |
EP10835373.1A EP2510926B1 (en) | 2009-12-08 | 2010-12-08 | Use of saturated amines compounds in manufacture of medicaments for mobilizing peripheral blood hematopoietic stem cell |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009102417263A CN101716167B (zh) | 2009-12-08 | 2009-12-08 | 一类饱和胺类化合物在制备外周血造血干细胞动员药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101716167A true CN101716167A (zh) | 2010-06-02 |
CN101716167B CN101716167B (zh) | 2011-12-28 |
Family
ID=42430864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009102417263A Expired - Fee Related CN101716167B (zh) | 2009-12-08 | 2009-12-08 | 一类饱和胺类化合物在制备外周血造血干细胞动员药物中的应用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20120322886A1 (zh) |
EP (1) | EP2510926B1 (zh) |
JP (1) | JP5667640B2 (zh) |
CN (1) | CN101716167B (zh) |
WO (1) | WO2011069336A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011069336A1 (zh) * | 2009-12-08 | 2011-06-16 | 中国人民解放军军事医学科学院野战输血研究所 | 一类饱和胺类化合物在制备外周血造血干细胞动员剂中的应用 |
CN102389408A (zh) * | 2011-10-20 | 2012-03-28 | 中国人民解放军军事医学科学院野战输血研究所 | 一种饱和胺类化合物在制备治疗缺血性疾病的药物中的应用 |
CN103110613A (zh) * | 2013-01-25 | 2013-05-22 | 中国人民解放军军事医学科学院野战输血研究所 | 饱和胺类化合物在制备抗辐射损伤药物中的应用 |
CN114891746A (zh) * | 2021-12-21 | 2022-08-12 | 青岛今墨堂生物技术有限公司 | 一种犬全血造血干细胞的制备方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017172976A1 (en) * | 2016-03-29 | 2017-10-05 | The Regents Of The University Of California | Methods for promoting oligodendrocyte regeneration and remyelination |
WO2021003432A1 (en) | 2019-07-02 | 2021-01-07 | Fred Hutchinson Cancer Research Center | Recombinant ad35 vectors and related gene therapy improvements |
WO2023150393A2 (en) | 2022-02-07 | 2023-08-10 | Ensoma, Inc. | Inhibitor-resistant mgmt modifications and modification of mgmt-encoding nucleic acids |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3767763A (en) * | 1971-11-26 | 1973-10-23 | Exxon Research Engineering Co | Separation of sodium compounds |
CA2344653A1 (en) * | 1998-09-29 | 2000-04-06 | Gamida Cell Ltd. | Methods of controlling proliferation and differentiation of stem and progenitor cells |
ES2380009T3 (es) * | 2001-07-31 | 2012-05-07 | Genzyme Global S.A.R.L. | Métodos para movilizar las células madre/progenitoras |
US7589197B2 (en) * | 2005-06-14 | 2009-09-15 | Taigen Biotechnology | Pyrimidine compounds |
CN101716167B (zh) * | 2009-12-08 | 2011-12-28 | 中国人民解放军军事医学科学院野战输血研究所 | 一类饱和胺类化合物在制备外周血造血干细胞动员药物中的应用 |
-
2009
- 2009-12-08 CN CN2009102417263A patent/CN101716167B/zh not_active Expired - Fee Related
-
2010
- 2010-12-08 EP EP10835373.1A patent/EP2510926B1/en active Active
- 2010-12-08 JP JP2012542340A patent/JP5667640B2/ja active Active
- 2010-12-08 US US13/514,873 patent/US20120322886A1/en not_active Abandoned
- 2010-12-08 WO PCT/CN2010/001986 patent/WO2011069336A1/zh active Application Filing
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011069336A1 (zh) * | 2009-12-08 | 2011-06-16 | 中国人民解放军军事医学科学院野战输血研究所 | 一类饱和胺类化合物在制备外周血造血干细胞动员剂中的应用 |
CN102389408A (zh) * | 2011-10-20 | 2012-03-28 | 中国人民解放军军事医学科学院野战输血研究所 | 一种饱和胺类化合物在制备治疗缺血性疾病的药物中的应用 |
CN102389408B (zh) * | 2011-10-20 | 2013-07-24 | 中国人民解放军军事医学科学院野战输血研究所 | 一种饱和胺类化合物在制备治疗缺血性疾病的药物中的应用 |
CN103110613A (zh) * | 2013-01-25 | 2013-05-22 | 中国人民解放军军事医学科学院野战输血研究所 | 饱和胺类化合物在制备抗辐射损伤药物中的应用 |
WO2014114254A1 (zh) * | 2013-01-25 | 2014-07-31 | 中国人民解放军军事医学科学院野战输血研究所 | 饱和胺类化合物在制备抗辐射损伤及促进辐射损伤组织再生修复药物中的应用 |
CN103110613B (zh) * | 2013-01-25 | 2014-10-22 | 中国人民解放军军事医学科学院野战输血研究所 | 饱和胺类化合物在制备抗辐射损伤药物中的应用 |
US9498451B2 (en) | 2013-01-25 | 2016-11-22 | Beijing Institute Of Transfusion Medicine, Academy Of Military Sciences | Method for treating or preventing radiation damage |
CN114891746A (zh) * | 2021-12-21 | 2022-08-12 | 青岛今墨堂生物技术有限公司 | 一种犬全血造血干细胞的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
JP5667640B2 (ja) | 2015-02-12 |
EP2510926B1 (en) | 2018-03-28 |
CN101716167B (zh) | 2011-12-28 |
EP2510926A4 (en) | 2013-08-21 |
EP2510926A1 (en) | 2012-10-17 |
US20120322886A1 (en) | 2012-12-20 |
JP2013512932A (ja) | 2013-04-18 |
WO2011069336A1 (zh) | 2011-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101716167B (zh) | 一类饱和胺类化合物在制备外周血造血干细胞动员药物中的应用 | |
Storb et al. | Treatment of established human graft-versus-host disease by antithymocyte globulin | |
CN105431521A (zh) | 用于动员干细胞的方法和组合物 | |
US10905717B2 (en) | Blood plasma and plasma fractions as therapy for tumor growth and progression | |
KR20180041229A (ko) | 줄기 세포 이식을 위한 방법 | |
Moog | Management strategies for poor peripheral blood stem cell mobilization | |
CN103320382A (zh) | 从胎盘和脐带中同时提取和纯化多种来源干细胞的方法 | |
CN116761606A (zh) | 增强细胞杀伤的药物组合物及其用途 | |
CN109731002B (zh) | 白酒草皂苷r用于制备造血干细胞动员剂的应用 | |
CN1179979C (zh) | 造血的阿拉伯半乳聚糖组合物 | |
CN103110613B (zh) | 饱和胺类化合物在制备抗辐射损伤药物中的应用 | |
Hull et al. | Transfusion-associated chronic cutaneous graft-versus-host disease | |
CN102389408B (zh) | 一种饱和胺类化合物在制备治疗缺血性疾病的药物中的应用 | |
CN107334756B (zh) | Gw3965用于制备防治肾缺血再灌注损伤药物的应用 | |
Wade | A Historical Review of Hematopoietic Stem Cell Transplantation: Developmental Advancements Then and Now | |
CN1277568C (zh) | 一种中草药药物组合物及其制备方法与用途 | |
ES2553590T3 (es) | Método de reparación y regeneración renal y el tratamiento de nefropatía diabética | |
KR102502770B1 (ko) | 알로페론으로 배양된 nk 세포를 함유하는 암 예방 또는 치료용 조성물 | |
CN109913413B (zh) | 一种加载pd-1抗体的t细胞体外培养方法、其细胞制剂及其应用 | |
Silingardi et al. | Recovery from aplastic anemia after treatment with antilymphocyte globulin | |
CN117980470A (zh) | 治疗性nk细胞群 | |
US20180296569A1 (en) | Cobalt porphyrins for the treatment of blood-related disorders | |
CN108404112A (zh) | 提高造血干细胞归巢及植入率的方法及其试剂 | |
Singh | Modification of tumor growth by blood transfusion and perioperative procedures: a study in rats | |
CN111000978A (zh) | Tlt-2在制备治疗结核病药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20100602 Assignee: SOUTH CHINA CENTER FOR STEM CELL BIOLOGY AND REGENERATIVE MEDICINE OF ACADEMY OF MILITARY MEDICAL SCIENCES Assignor: INSTITUE OF TRANSFUSION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PEOPLE'S LIBRATION ARMY OF CHINA Contract record no.: 2015990000123 Denomination of invention: Use of saturated amine compound in preparation of medicaments for mobilizing peripheral blood hematopoietic stem cells Granted publication date: 20111228 License type: Exclusive License Record date: 20150324 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111228 |